B
Catalyst Pharmaceuticals, Inc.
CPRX
$21.02
$0.150.72%
B
Buy
3/5/2025Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to B- from B on 3/5/2025 due to a large decline in the total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to B- from B on 3/5/2025 due to a large decline in the total return index.
B
Buy
2/27/2025Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B from B- on 2/27/2025 due to a noticeable increase in the total return index and valuation index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B from B- on 2/27/2025 due to a noticeable increase in the total return index and valuation index.
B
Buy
2/7/2025Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to B- from B on 2/7/2025 due to a large decline in the total return index, valuation index and volatility index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to B- from B on 2/7/2025 due to a large decline in the total return index, valuation index and volatility index.
B
Buy
1/21/2025Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B from B- on 1/21/2025 due to a large increase in the total return index and volatility index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B from B- on 1/21/2025 due to a large increase in the total return index and volatility index.
B
Buy
1/6/2025Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to B- from B on 1/6/2025 due to a large decline in the total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to B- from B on 1/6/2025 due to a large decline in the total return index.
B
Buy
11/8/2024Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B from C+ on 11/8/2024 due to a significant increase in the growth index, valuation index and efficiency index. Operating cash flow increased 13.62% from $64.14M to $72.87M, total capital increased 8.53% from $612.03M to $664.22M, and net income increased 7.57% from $40.79M to $43.88M.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B from C+ on 11/8/2024 due to a significant increase in the growth index, valuation index and efficiency index. Operating cash flow increased 13.62% from $64.14M to $72.87M, total capital increased 8.53% from $612.03M to $664.22M, and net income increased 7.57% from $40.79M to $43.88M.
C
Hold
10/10/2024Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C+ from C on 10/10/2024 due to a large increase in the total return index, valuation index and volatility index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C+ from C on 10/10/2024 due to a large increase in the total return index, valuation index and volatility index.
C
Hold
9/24/2024Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C from C+ on 9/24/2024 due to a decline in the total return index and valuation index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C from C+ on 9/24/2024 due to a decline in the total return index and valuation index.
C
Hold
9/5/2024Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C+ from C on 9/5/2024 due to an increase in the total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C+ from C on 9/5/2024 due to an increase in the total return index.
C
Hold
8/19/2024Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C from C+ on 8/19/2024 due to a large decline in the total return index, valuation index and volatility index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C from C+ on 8/19/2024 due to a large decline in the total return index, valuation index and volatility index.
C
Hold
8/7/2024Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C+ from C on 8/7/2024 due to a major increase in the total return index and volatility index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C+ from C on 8/7/2024 due to a major increase in the total return index and volatility index.
C
Hold
5/14/2024Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C from C+ on 5/14/2024 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 42.63% from $55.65M to $31.93M, earnings per share declined from $0.31 to $0.19, and EBIT declined 34.94% from $41.69M to $27.13M.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C from C+ on 5/14/2024 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 42.63% from $55.65M to $31.93M, earnings per share declined from $0.31 to $0.19, and EBIT declined 34.94% from $41.69M to $27.13M.
C
Hold
4/3/2024Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C+ from C on 4/3/2024 due to a significant increase in the growth index, total return index and volatility index. EBIT increased 212.11% from -$37.19M to $41.69M, earnings per share increased from -$0.29 to $0.31, and operating cash flow increased 23.31% from $45.13M to $55.65M.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C+ from C on 4/3/2024 due to a significant increase in the growth index, total return index and volatility index. EBIT increased 212.11% from -$37.19M to $41.69M, earnings per share increased from -$0.29 to $0.31, and operating cash flow increased 23.31% from $45.13M to $55.65M.
C
Hold
11/9/2023Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C from C+ on 11/9/2023 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.33 to -$0.29, net income declined 181.47% from $37.76M to -$30.76M, and EBIT declined 179.63% from $46.7M to -$37.19M.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C from C+ on 11/9/2023 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.33 to -$0.29, net income declined 181.47% from $37.76M to -$30.76M, and EBIT declined 179.63% from $46.7M to -$37.19M.
C
Hold
11/6/2023Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C+ from B- on 11/6/2023 due to a decline in the efficiency index, valuation index and total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C+ from B- on 11/6/2023 due to a decline in the efficiency index, valuation index and total return index.
B
Buy
10/12/2023Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B- from C+ on 10/12/2023 due to an increase in the valuation index, growth index and efficiency index. Operating cash flow increased 154.8% from $12.07M to $30.75M, EBIT increased 31.14% from $35.61M to $46.7M, and net income increased 27.71% from $29.57M to $37.76M.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B- from C+ on 10/12/2023 due to an increase in the valuation index, growth index and efficiency index. Operating cash flow increased 154.8% from $12.07M to $30.75M, EBIT increased 31.14% from $35.61M to $46.7M, and net income increased 27.71% from $29.57M to $37.76M.
C
Hold
5/24/2023Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C+ from B- on 5/24/2023 due to a decline in the volatility index, total return index and growth index. Operating cash flow declined 69.88% from $40.08M to $12.07M.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C+ from B- on 5/24/2023 due to a decline in the volatility index, total return index and growth index. Operating cash flow declined 69.88% from $40.08M to $12.07M.
B
Buy
5/5/2023Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to B- from B on 5/5/2023 due to a substantial decline in the total return index, volatility index and growth index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to B- from B on 5/5/2023 due to a substantial decline in the total return index, volatility index and growth index.
B
Buy
4/20/2023Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B from B- on 4/20/2023 due to a large increase in the total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B from B- on 4/20/2023 due to a large increase in the total return index.
B
Buy
4/5/2023Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to B- from B on 4/5/2023 due to a significant decline in the total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to B- from B on 4/5/2023 due to a significant decline in the total return index.
B
Buy
7/14/2022Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B from B- on 7/14/2022 due to a significant increase in the total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B from B- on 7/14/2022 due to a significant increase in the total return index.
B
Buy
6/30/2022Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B- from C+ on 6/30/2022 due to an increase in the total return index and valuation index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B- from C+ on 6/30/2022 due to an increase in the total return index and valuation index.
C
Hold
6/14/2022Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C+ from B- on 6/14/2022 due to a decline in the total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C+ from B- on 6/14/2022 due to a decline in the total return index.
B
Buy
5/27/2022Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to B- from B on 5/27/2022 due to a significant decline in the total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to B- from B on 5/27/2022 due to a significant decline in the total return index.
B
Buy
5/12/2022Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B from B- on 5/12/2022 due to a large increase in the growth index, total return index and efficiency index. Net income increased 42.24% from $9.31M to $13.24M, EBIT increased 36.29% from $12.74M to $17.37M, and earnings per share increased from $0.0899 to $0.12.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B from B- on 5/12/2022 due to a large increase in the growth index, total return index and efficiency index. Net income increased 42.24% from $9.31M to $13.24M, EBIT increased 36.29% from $12.74M to $17.37M, and earnings per share increased from $0.0899 to $0.12.
B
Buy
2/16/2022Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B- from C+ on 2/16/2022 due to a large increase in the total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B- from C+ on 2/16/2022 due to a large increase in the total return index.
C
Hold
1/21/2022Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C+ from B- on 1/21/2022 due to a noticeable decline in the total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C+ from B- on 1/21/2022 due to a noticeable decline in the total return index.
B
Buy
12/6/2021Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B- from C+ on 12/6/2021 due to an increase in the total return index and volatility index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B- from C+ on 12/6/2021 due to an increase in the total return index and volatility index.
C
Hold
11/10/2021Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C+ from B- on 11/10/2021 due to a substantial decline in the valuation index and growth index. EBIT declined 11.58% from $15.84M to $14M, earnings per share declined from $0.1131 to $0.1, and total revenue declined 1.13% from $36.37M to $35.95M.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C+ from B- on 11/10/2021 due to a substantial decline in the valuation index and growth index. EBIT declined 11.58% from $15.84M to $14M, earnings per share declined from $0.1131 to $0.1, and total revenue declined 1.13% from $36.37M to $35.95M.
B
Buy
10/20/2021Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B- from C+ on 10/20/2021 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 310.99% from $3.81M to $15.68M, EBIT increased 61.6% from $9.8M to $15.84M, and earnings per share increased from $0.07 to $0.1131.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to B- from C+ on 10/20/2021 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 310.99% from $3.81M to $15.68M, EBIT increased 61.6% from $9.8M to $15.84M, and earnings per share increased from $0.07 to $0.1131.
C
Hold
5/11/2021Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C+ from C on 5/11/2021 due to an increase in the efficiency index and total return index. Total capital increased 7.75% from $169.63M to $182.78M.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C+ from C on 5/11/2021 due to an increase in the efficiency index and total return index. Total capital increased 7.75% from $169.63M to $182.78M.
C
Hold
4/15/2021Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C from C- on 4/15/2021 due to an increase in the volatility index and total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C from C- on 4/15/2021 due to an increase in the volatility index and total return index.
C
Hold
3/16/2021Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C- from C on 3/16/2021 due to a major decline in the total return index, growth index and volatility index. Earnings per share declined from $0.41 to $0.1096, and EBIT declined 26.37% from $11.7M to $8.62M.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C- from C on 3/16/2021 due to a major decline in the total return index, growth index and volatility index. Earnings per share declined from $0.41 to $0.1096, and EBIT declined 26.37% from $11.7M to $8.62M.
C
Hold
8/13/2020Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C from C- on 8/13/2020 due to a large increase in the total return index, growth index and efficiency index. Operating cash flow increased 83.9% from $7.21M to $13.27M, total capital increased 10.79% from $100.55M to $111.4M, and total revenue increased 1.61% from $29.14M to $29.6M.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C from C- on 8/13/2020 due to a large increase in the total return index, growth index and efficiency index. Operating cash flow increased 83.9% from $7.21M to $13.27M, total capital increased 10.79% from $100.55M to $111.4M, and total revenue increased 1.61% from $29.14M to $29.6M.
C
Hold
8/10/2020Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C- from C on 8/10/2020 due to a decline in the total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C- from C on 8/10/2020 due to a decline in the total return index.
C
Hold
6/25/2020Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C from C- on 6/25/2020 due to an increase in the total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C from C- on 6/25/2020 due to an increase in the total return index.
C
Hold
5/29/2020Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C- from C on 5/29/2020 due to a decline in the total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C- from C on 5/29/2020 due to a decline in the total return index.
C
Hold
5/14/2020Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C from C- on 5/14/2020 due to an increase in the total return index and valuation index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C from C- on 5/14/2020 due to an increase in the total return index and valuation index.
C
Hold
5/13/2020Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C- from D+ on 5/13/2020 due to a major increase in the growth index, efficiency index and volatility index. Earnings per share increased from $0.0701 to $0.1, EBIT increased 33.63% from $8.01M to $10.7M, and net income increased 31.48% from $7.93M to $10.43M.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C- from D+ on 5/13/2020 due to a major increase in the growth index, efficiency index and volatility index. Earnings per share increased from $0.0701 to $0.1, EBIT increased 33.63% from $8.01M to $10.7M, and net income increased 31.48% from $7.93M to $10.43M.
D
Sell
3/17/2020Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D+ from C- on 3/17/2020 due to a significant decline in the growth index, volatility index and efficiency index. Earnings per share declined from $0.13 to $0.07, EBIT declined 42.17% from $13.85M to $8.01M, and net income declined 41.82% from $13.63M to $7.93M.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D+ from C- on 3/17/2020 due to a significant decline in the growth index, volatility index and efficiency index. Earnings per share declined from $0.13 to $0.07, EBIT declined 42.17% from $13.85M to $8.01M, and net income declined 41.82% from $13.63M to $7.93M.
C
Hold
12/17/2019Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C- from C on 12/17/2019 due to a large decline in the total return index, growth index and efficiency index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to C- from C on 12/17/2019 due to a large decline in the total return index, growth index and efficiency index.
C
Hold
11/13/2019Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C from D+ on 11/13/2019 due to a major increase in the efficiency index, valuation index and total return index. Net income increased 24.36% from $10.96M to $13.63M, and total capital increased 22.27% from $64.37M to $78.71M.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C from D+ on 11/13/2019 due to a major increase in the efficiency index, valuation index and total return index. Net income increased 24.36% from $10.96M to $13.63M, and total capital increased 22.27% from $64.37M to $78.71M.
D
Sell
8/8/2019Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to D+ from D- on 8/8/2019 due to a significant increase in the growth index, total return index and efficiency index. Net income increased 1,800.53% from -$644.5 to $10.96M, earnings per share increased from -$0.0063 to $0.1, and EBIT increased 1,209.46% from -$987.8 to $10.96M.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to D+ from D- on 8/8/2019 due to a significant increase in the growth index, total return index and efficiency index. Net income increased 1,800.53% from -$644.5 to $10.96M, earnings per share increased from -$0.0063 to $0.1, and EBIT increased 1,209.46% from -$987.8 to $10.96M.
D
Sell
3/29/2019Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D- from D on 3/29/2019 due to a noticeable decline in the growth index, efficiency index and valuation index. Net income declined 84.97% from -$7.84M to -$14.5M, earnings per share declined from -$0.0764 to -$0.1411, and EBIT declined 81.4% from -$8.18M to -$14.84M.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D- from D on 3/29/2019 due to a noticeable decline in the growth index, efficiency index and valuation index. Net income declined 84.97% from -$7.84M to -$14.5M, earnings per share declined from -$0.0764 to -$0.1411, and EBIT declined 81.4% from -$8.18M to -$14.84M.
D
Sell
3/15/2018Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to D from D- on 3/15/2018 due to an increase in the efficiency index, solvency index and valuation index. Total capital increased 155.17% from $31.73M to $80.96M, and the quick ratio increased from 12.39 to 19.69.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to D from D- on 3/15/2018 due to an increase in the efficiency index, solvency index and valuation index. Total capital increased 155.17% from $31.73M to $80.96M, and the quick ratio increased from 12.39 to 19.69.
D
Sell
11/8/2017Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D- from D on 11/8/2017 due to a decline in the volatility index and valuation index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D- from D on 11/8/2017 due to a decline in the volatility index and valuation index.
D
Sell
10/24/2017Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to D from D- on 10/24/2017 due to an increase in the total return index and volatility index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to D from D- on 10/24/2017 due to an increase in the total return index and volatility index.
D
Sell
10/9/2017Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D- from D on 10/9/2017 due to a decline in the valuation index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D- from D on 10/9/2017 due to a decline in the valuation index.
D
Sell
9/18/2017Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to D from D- on 9/18/2017 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.0599 to -$0.0462, operating cash flow increased 17.48% from -$3.88M to -$3.2M, and EBIT increased 10.65% from -$4.68M to -$4.18M.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to D from D- on 9/18/2017 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.0599 to -$0.0462, operating cash flow increased 17.48% from -$3.88M to -$3.2M, and EBIT increased 10.65% from -$4.68M to -$4.18M.
D
Sell
5/12/2017Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D- from D on 5/12/2017 due to a decline in the valuation index, efficiency index and solvency index. Net income declined 19.31% from -$4.16M to -$4.97M, total capital declined 10.72% from $39.31M to $35.1M, and the quick ratio declined from 19.29 to 19.17.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D- from D on 5/12/2017 due to a decline in the valuation index, efficiency index and solvency index. Net income declined 19.31% from -$4.16M to -$4.97M, total capital declined 10.72% from $39.31M to $35.1M, and the quick ratio declined from 19.29 to 19.17.
D
Sell
9/22/2016Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to D from D- on 9/22/2016 due to a large increase in the growth index, volatility index and efficiency index. Operating cash flow increased 26.76% from -$5.93M to -$4.34M, EBIT increased 22.81% from -$6.24M to -$4.81M, and earnings per share increased from -$0.065 to -$0.0551.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to D from D- on 9/22/2016 due to a large increase in the growth index, volatility index and efficiency index. Operating cash flow increased 26.76% from -$5.93M to -$4.34M, EBIT increased 22.81% from -$6.24M to -$4.81M, and earnings per share increased from -$0.065 to -$0.0551.
D
Sell
5/4/2016Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D- from D on 5/4/2016 due to a noticeable decline in the volatility index, growth index and efficiency index. Net income declined 30.71% from -$4.45M to -$5.82M, earnings per share declined from -$0.0539 to -$0.0702, and EBIT declined 23.4% from -$5.02M to -$6.19M.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D- from D on 5/4/2016 due to a noticeable decline in the volatility index, growth index and efficiency index. Net income declined 30.71% from -$4.45M to -$5.82M, earnings per share declined from -$0.0539 to -$0.0702, and EBIT declined 23.4% from -$5.02M to -$6.19M.
D
Sell
3/11/2016Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
D
Sell
1/25/2016Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D+ from C- on 1/25/2016 due to a decline in the total return index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D+ from C- on 1/25/2016 due to a decline in the total return index.
C
Hold
1/8/2016Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C- from D+ on 1/8/2016 due to an increase in the valuation index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to C- from D+ on 1/8/2016 due to an increase in the valuation index.
D
Sell
11/10/2015Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to D+ from D on 11/10/2015 due to an increase in the valuation index, efficiency index and solvency index.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to D+ from D on 11/10/2015 due to an increase in the valuation index, efficiency index and solvency index.
D
Sell
10/28/2015Downgrade
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D from D+ on 10/28/2015 due to a noticeable decline in the total return index, volatility index and valuation index.
Catalyst Pharmaceuticals, Inc. (CPRX) was downgraded to D from D+ on 10/28/2015 due to a noticeable decline in the total return index, volatility index and valuation index.
D
Sell
10/12/2015Upgraded
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to D+ from D on 10/12/2015 due to a significant increase in the volatility index, total return index and growth index. EBIT increased 14.11% from -$4.29M to -$4.9M, and operating cash flow increased 11.88% from -$3.8M to -$4.25M.
Catalyst Pharmaceuticals, Inc. (CPRX) was upgraded to D+ from D on 10/12/2015 due to a significant increase in the volatility index, total return index and growth index. EBIT increased 14.11% from -$4.29M to -$4.9M, and operating cash flow increased 11.88% from -$3.8M to -$4.25M.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
